Upgrading a mass spectrometry facility for advanced proteomics research
A Bruker timsTOF HT mass spectrometer and nanoflow LC system to upgrade the proteomics facility at Rutgers-New Brunswick and Robert Wood Johnson Medical School
This study is all about getting new, advanced equipment to help scientists at Rutgers and Robert Wood Johnson Medical School better understand proteins, which can help them learn more about diseases like cancer and metabolic disorders, ultimately leading to new treatments that could help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10851372 on NIH RePORTER |
What this research studies
This research aims to enhance the capabilities of the proteomics facility at Rutgers-New Brunswick and Robert Wood Johnson Medical School by acquiring a state-of-the-art Bruker timsTOF HT mass spectrometer and NanoElute 2 liquid chromatography system. This new equipment will allow for more accurate and comprehensive analysis of proteins, which is crucial for understanding various diseases, including cancers and metabolic disorders. By integrating this advanced technology, researchers will be able to conduct more detailed studies on protein interactions and functions, ultimately leading to better insights into disease mechanisms. Patients may benefit indirectly through improved research outcomes that could lead to new treatments or diagnostic tools.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals affected by conditions such as cancer, diabetes, and other diseases that involve protein abnormalities.
Not a fit: Patients with conditions unrelated to protein analysis or those not participating in research studies at the facility may not receive direct benefits.
Why it matters
Potential benefit: If successful, this research could lead to significant advancements in the understanding and treatment of various diseases, including cancer and diabetes.
How similar studies have performed: Previous research has shown success with similar mass spectrometry approaches in enhancing proteomics capabilities, indicating a strong potential for impactful outcomes.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Zheng, Haiyan — Rutgers Biomedical and Health Sciences
- Study coordinator: Zheng, Haiyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.